Drug Trial Radar · NCT06765161
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Feb 6, 2025
Primary completion
Jan 6, 2027
Study completion Jan 6, 2027
Sponsor
- Lead sponsor
- Clinique Neuro-OutaouaisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- argenx
- First posted
- Jan 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.
Conditions
- Myasthaenia Gravis
Interventions
efgartigimod administrationDrug
efgartigimod infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- MG-ADLTime frame: a sustained decrease persistent for at least 4 consecutive weeks over the 26 week period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinique Neuro-Outaouais
Gatineau, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.